Barclays PLC Has $1.68 Million Holdings in GSK plc (NYSE:GSK)

Barclays PLC lifted its holdings in GSK plc (NYSE:GSK - Free Report) by 84.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 49,628 shares of the pharmaceutical company's stock after purchasing an additional 22,689 shares during the quarter. Barclays PLC's holdings in GSK were worth $1,678,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. FMR LLC increased its position in shares of GSK by 82.1% during the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock worth $1,786,475,000 after acquiring an additional 23,814,104 shares in the last quarter. Primecap Management Co. CA increased its holdings in GSK by 70.1% during the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock worth $854,349,000 after purchasing an additional 10,407,905 shares in the last quarter. Mondrian Investment Partners LTD lifted its holdings in shares of GSK by 17.6% in the fourth quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company's stock valued at $205,920,000 after purchasing an additional 874,004 shares in the last quarter. Miller Howard Investments Inc. NY bought a new stake in GSK in the 4th quarter valued at approximately $23,366,000. Finally, Equity Investment Corp boosted its holdings in GSK by 13.3% during the fourth quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company's stock worth $134,014,000 after purchasing an additional 466,327 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Analysts Set New Price Targets

GSK has been the topic of a number of recent research reports. BNP Paribas started coverage on GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price on the stock. Morgan Stanley assumed coverage on GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Finally, StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $40.58.

GSK Stock Performance

Shares of GSK traded down $0.45 during trading hours on Thursday, hitting $36.72. The company had a trading volume of 997,351 shares, compared to its average volume of 5,270,277. The business has a fifty day moving average of $37.71 and a 200-day moving average of $36.02. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a market cap of $75.76 billion, a price-to-earnings ratio of 23.09, a PEG ratio of 1.12 and a beta of 0.51. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The firm had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. During the same period last year, the business posted $0.43 earnings per share. The business's revenue for the quarter was up 2.1% compared to the same quarter last year. Equities analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be given a dividend of $0.4216 per share. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 annualized dividend and a yield of 4.59%. GSK's dividend payout ratio (DPR) is presently 86.60%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.